These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 12646019)
1. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. Sun L; Liang C; Shirazian S; Zhou Y; Miller T; Cui J; Fukuda JY; Chu JY; Nematalla A; Wang X; Chen H; Sistla A; Luu TC; Tang F; Wei J; Tang C J Med Chem; 2003 Mar; 46(7):1116-9. PubMed ID: 12646019 [TBL] [Abstract][Full Text] [Related]
2. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303 [TBL] [Abstract][Full Text] [Related]
3. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. Moss KG; Toner GC; Cherrington JM; Mendel DB; Laird AD J Pharmacol Exp Ther; 2003 Nov; 307(2):476-80. PubMed ID: 12966161 [TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485 [TBL] [Abstract][Full Text] [Related]
5. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. Sun L; Tran N; Liang C; Tang F; Rice A; Schreck R; Waltz K; Shawver LK; McMahon G; Tang C J Med Chem; 1999 Dec; 42(25):5120-30. PubMed ID: 10602697 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163 [TBL] [Abstract][Full Text] [Related]
8. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546 [TBL] [Abstract][Full Text] [Related]
9. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, in silico, in vitro, and in vivo investigation of 5-[¹¹C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2. Caballero J; Muñoz C; Alzate-Morales JH; Cunha S; Gano L; Bergmann R; Steinbach J; Kniess T Eur J Med Chem; 2012 Dec; 58():272-80. PubMed ID: 23131541 [TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
13. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Gangjee A; Zaware N; Raghavan S; Ihnat M; Shenoy S; Kisliuk RL J Med Chem; 2010 Feb; 53(4):1563-78. PubMed ID: 20092323 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives. Li HH; Zheng XH; Tan JZ; Chen LL; Liu H; Luo XM; Shen X; Lin LP; Chen KX; Ding J; Jiang HL Acta Pharmacol Sin; 2007 Jan; 28(1):140-52. PubMed ID: 17184594 [TBL] [Abstract][Full Text] [Related]
15. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. Mahboobi S; Uecker A; Sellmer A; Cénac C; Höcher H; Pongratz H; Eichhorn E; Hufsky H; Trümpler A; Sicker M; Heidel F; Fischer T; Stocking C; Elz S; Böhmer FD; Dove S J Med Chem; 2006 Jun; 49(11):3101-15. PubMed ID: 16722630 [TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile. Chiang CC; Lin YH; Lin SF; Lai CL; Liu C; Wei WY; Yang SC; Wang RW; Teng LW; Chuang SH; Chang JM; Yuan TT; Lee YS; Chen P; Chi WK; Yang JY; Huang HJ; Liao CB; Huang JJ J Med Chem; 2010 Aug; 53(16):5929-41. PubMed ID: 20681538 [TBL] [Abstract][Full Text] [Related]
17. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047 [TBL] [Abstract][Full Text] [Related]